Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome
- PMID: 32400965
- PMCID: PMC7273014
- DOI: 10.1111/ajt.15992
Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome
Keywords: antibiotic: antiviral; clinical research/practice; complication: infectious; drug interaction; infectious disease; kidney transplantation/nephrology; liver transplantation/hepatology.
Comment on
-
COVID-19 in solid organ transplant recipients: A single-center case series from Spain.Am J Transplant. 2020 Jul;20(7):1849-1858. doi: 10.1111/ajt.15929. Epub 2020 May 10. Am J Transplant. 2020. PMID: 32301155 Free PMC article.
References
-
- Prytuła A, van Gelder T. Clinical aspects of tacrolimus use in paediatric renal transplant recipients. Pediatr Nephrol. 2019;34(1):31–43. - PubMed
-
- Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003;9(9):954–960. - PubMed
-
- Ehud C, Matthew D, Eric S, et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv preprint. 2020. 10.1101/2020.04.02.20047050 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
